Kopra Bio
June 25, 2026
Theater 1
Type: Company Presentation
Focus Area:
Oncology
Kopra Bio uses genetically engineered viruses to reprogram cancer cells to make cancer cures. The team has developed our InViTE (In Vivo Tumor Engineering) platform that selectively infects solid tumor cells and reprograms them into produce therapeutic payloads. Our lead asset, KB-516, achieved a 90% complete response rate in aggressive preclinical solid tumor models and is slated to enter the clinic in early 2027.
Company HQ City:
San Francisco
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2024
Lead Product in Development:
KB-516 is a tumor-targeted replicating retroviral vector expressing an immune-stimulatory cytokine IL-15 superagonist.
CEO
Andrew Bartynski
Development Phase of Lead Product
Pre-Clinical
When you expect your next catalyst update?
Q1 2027
What is your next catalyst (value inflection) update?
First in human clinical studies
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}